Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A gabapentinoid is a medicine related structurally to gamma-aminobutyric acid but acting mainly through alpha-2-delta subunits of voltage-gated calcium channels. Gabapentin and pregabalin are the main drugs in this group. They are used for selected seizure disorders and several forms of neuropathic pain. Despite their name and structure, they do not act directly as gamma-aminobutyric acid receptor agonists.
read more about gabapentinoid ...Gabapentinoids are used as adjunctive treatment for certain partial-onset seizures and for selected types of nerve pain. Approved uses vary by drug and product and can include postherpetic neuralgia, diabetic peripheral neuropathy, spinal cord injury pain, fibromyalgia, or restless legs syndrome. They are also prescribed off label for some conditions, although evidence is not equally strong for every pain problem. The specific diagnosis, kidney function, other medicines, and risk of sedation affect treatment selection.
Gabapentinoids bind to alpha-2-delta auxiliary subunits associated with voltage-gated calcium channels. This action changes calcium-channel trafficking and can reduce the release of excitatory neurotransmitters in overactive nerve pathways. The result can reduce abnormal electrical activity or neuropathic pain signaling. Their clinical effects are not produced by directly stimulating gamma-aminobutyric acid receptors.
Gabapentinoids are available in immediate-release and selected extended-release oral formulations. Doses are commonly started low and increased gradually according to response and tolerability. The kidneys remove much of the drug, so reduced kidney function can require a lower dose or longer dosing interval. Treatment should be tapered rather than stopped suddenly when withdrawal symptoms or seizure worsening are a concern.
Common effects include dizziness, sleepiness, blurred vision, impaired coordination, swelling, and weight gain. Serious breathing problems can occur, particularly when a gabapentinoid is combined with opioids or other central nervous system depressants or used by someone with respiratory risk factors. Misuse, physical dependence, and withdrawal symptoms have also been reported. Severe sedation, confusion, bluish lips, or slow, shallow, or difficult breathing requires urgent medical attention.
No. Gabapentinoids are not opioids and act through different molecular targets. Combining them with opioids can still increase sedation and respiratory risk.
No. They are structurally related to gamma-aminobutyric acid but do not directly activate its receptors. Their main recognized target is the alpha-2-delta subunit associated with voltage-gated calcium channels.
Yes. Abrupt discontinuation can cause symptoms such as anxiety, insomnia, nausea, sweating, pain, or seizures in susceptible patients. A prescriber can provide an appropriate taper.
Gabapentin and pregabalin are removed mainly through the kidneys. Reduced kidney clearance can cause the medicine to accumulate and increase adverse effects.
Gabapentin. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK493228/. Date Accessed August 5, 2026.
Pregabalin. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK470341/. Date Accessed August 5, 2026.
Gabapentin and Pregabalin: Drug Safety Communication. U.S. Food and Drug Administration. https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication. Date Accessed August 5, 2026.
Gabapentinoids: Pharmacokinetics, Pharmacodynamics and Considerations for Clinical Practice. British Journal of Pain (PubMed Central). https://pmc.ncbi.nlm.nih.gov/articles/PMC7265598/. Date Accessed August 5, 2026.
LYRICA (Pregabalin) Capsules and Oral Solution: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9&type=display. Date Accessed August 5, 2026.